Neurocrine Biosciences (NASDAQ: NBIX) insider donates 2,441 shares

Rhea-AI Filing Summary

Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported a charitable stock gift. On June 5, 2026, Onyia transferred 2,441 shares of common stock as a bona fide gift, with no price reported and no value received. Following the gift, Onyia directly holds 23,405 common shares. The filing notes this was not a market transaction, so it does not reflect open-market buying or selling activity.

Insider Trade Summary

2,441 shares gifted

Mixed 1 txn

Insider Onyia Jude

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	2,441	$0.00	--

Holdings After Transaction: Common Stock — 23,405 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares gifted: 2,441 shares Shares held after transaction: 23,405 shares Transaction price per share: $0.00 +1 more

4 metrics

Shares gifted 2,441 shares Bona fide gift effective June 5, 2026

Shares held after transaction 23,405 shares Direct ownership after gift

Transaction price per share $0.00 Gift; not a market transaction

Transaction type Bona fide gift Non-derivative common stock disposition

Key Terms

bona fide gift, Form 4, Chief Scientific Officer, non-derivative

4 terms

bona fide gift financial

"This transaction represents a gift/charitable contribution effective June 5, 2026."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): { "issuerName": "NEUROCRINE BIOSCIENCES INC""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Scientific Officer financial

""officer_title": "Chief Scientific Officer""

non-derivative financial

""transaction_type": "non-derivative""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 06:51 PM Accepted by SEC EDGAR 06/09/2026 - 05:34 PM Learn about SEC filing dates

FAQ

What did NBIX Chief Scientific Officer Jude Onyia report in this Form 4?

Jude Onyia reported a bona fide gift of 2,441 shares of Neurocrine Biosciences common stock. The transaction was a charitable contribution, not an open-market trade, and no cash or other value was received for the transferred shares.

How many NBIX shares did Jude Onyia gift, and on what date?

Onyia gifted 2,441 shares of Neurocrine Biosciences common stock effective June 5, 2026. The Form 4 describes the transaction as a bona fide gift or charitable contribution and clarifies that it was not executed in the open market.

Does the Form 4 for NBIX indicate a buy or sell by Jude Onyia?

The Form 4 does not show a buy or sell; it shows a gift disposition. Shares were transferred as a bona fide gift, with no price reported and no value received, so it is not considered an open-market purchase or sale of NBIX stock.

How many NBIX shares does Jude Onyia hold after the reported gift?

After the 2,441-share gift, Onyia directly holds 23,405 shares of Neurocrine Biosciences common stock. This post-transaction holding figure comes directly from the Form 4 and reflects Onyia’s remaining direct ownership position following the charitable transfer.

Was any price or value reported for Jude Onyia’s NBIX stock gift?

No price or value was reported for the gift. The Form 4 footnote explains that the 2,441-share transfer is a gift or charitable contribution, is not a market transaction, and that no value was received for the shares given away.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Onyia Jude

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		G(1)		2,441	D	$0	23,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a gift/charitable contribution effective June 5, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)